# EDGAR Filing Document

**Accession Number:** 0001873835
**File Stem:** 0001493152-26-012722
**Filing Date:** 2026-3
**Character Count:** 19666
**Document Hash:** bf1488960c7e4b3a58c99c354f16ccda
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-012722.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0001493152-26-012722

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260325

**DATE AS OF CHANGE**: 20260325

**EFFECTIVENESS DATE**: 20260325

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immix Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001873835
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 454869378
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294613
- **FILM NUMBER:** 26793629

**BUSINESS ADDRESS:**
- **STREET 1:** 11400 WEST OLYMPIC BLVD.
- **STREET 2:** SUITE 200
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064
- **BUSINESS PHONE:** (888) 958-1084

**MAIL ADDRESS:**
- **STREET 1:** 10573 W. PICO BLVD.
- **STREET 2:** #58
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064

**As filed with the Securities and Exchange Commission on March 25, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**Immix Biopharma, Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **45-4869378** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **11400 West Olympic Blvd., Suite 200**<br> **Los Angeles, CA** | **90064** |
| (Address of principal executive offices) | (Zip Code) |

---

**AMENDED AND RESTATED**

**IMMIX BIOPHARMA, INC.**

**2021 OMNIBUS EQUITY INCENTIVE PLAN**

(Full title of the plan)

**Ilya Rachman, MD PhD**

**Chief Executive Officer**

**11400 West Olympic Blvd., Suite 200**

**Los Angeles, CA 90064**

(Name and address of agent for service)

**(310) 651-8041**

(Telephone number, including area code, of agent for service)

***Copies to:***

 ****

---

| | |
|:---|:---|
| **Gabriel Morris<br> Chief Financial Officer**<br> **Immix Biopharma, Inc.** | **Leslie Marlow, Esq.<br> Melissa Palat Murawsky, Esq.**<br> **Blank Rome LLP** |
| **11400 West Olympic Blvd., Suite 200<br> Los Angeles, CA 90064**<br> **Telephone: (310) 651-8041** | **1271 Avenue of the Americas**<br> **New York, New York 10020**<br> **Telephone: (212) 885-5000** |

---

 ****

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "<u>large accelerated filer</u>," "<u>accelerated filer</u>," "<u>smaller reporting company</u>," and "<u>emerging growth company</u>" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

Immix Biopharma, Inc. (the "<u>Registrant</u>") is filing this Registration Statement on Form S-8 (the "<u>Registration Statement</u>") with the Securities and Exchange Commission (the "<u>SEC</u>") to register an additional 4,024,556 shares (the "<u>Shares</u>") of the Registrant's common stock, par value $0.0001 per share (the "<u>Common Stock</u>") issuable upon the grant, exercise or vesting of awards pursuant to the Registrant's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "<u>Plan</u>") resulting from (i) an automatic increase pursuant to the "evergreen" provision in the Plan of 1,377,001 shares of Common Stock, such number of shares equal to 5% of the total number of shares of Common Stock outstanding as of December 31, 2024; and (ii) an automatic increase pursuant to the "evergreen" provision in the Plan of 2,647,555 shares of Common Stock, such number of shares equal to 5% of the total number of shares of Common Stock outstanding as of December 31, 2025. The Shares are in addition to and of the same class as the Common Stock for which the Registrant previously filed with the SEC: a Registration Statement on Form S-8 on July 22, 2024 (File No. 333-280929), a Registration Statement on Form S-8 on June 13, 2023 (File No. 333-272625) and a Registration Statement on Form S-8 on January 25, 2022 (File No. 333-262336) (collectively, the "<u>Prior Registration Statements</u>"). Pursuant to Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated by reference into this Registration Statement.

**Part II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference**

The following documents filed with the Commission by the Company are incorporated by reference into this registration statement on Form S-8 (the "<u>Registration Statement</u>") and are made a part hereof:

&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 Company's Annual Report on Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1873835/000149315226012714/form10-k.htm) for the year ended December 31, 2025, filed with the SEC on March 25,
 2026; and

(b) The
 description of our common stock contained in the Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1873835/000149315221031289/form8a-12b.htm) , as filed
 with the SEC on December 13, 2021 (File No. 001-41159), including any amendments thereto
 or reports filed for the purposes of updating this description.

All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the date of filing this Registration Statement and prior to such time as the Company files a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents, except for the documents, or portions thereof, that are "furnished" rather than filed with the SEC.

**Item 8. Exhibits**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| <br>**Exhibit No.** | <br>**Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** | **Filed**<br>**Herewith** |
| 5.1\* | [Opinion of Blank Rome LLP](ex5-1.htm) |  |  |  |  | X |
| 23.1\* | [Consent of Crowe LLP](ex23-1.htm) |  |  |  |  | X |
| 23.2\* | [Consent of Blank Rome LLP (included in Exhibit 5.1)](ex5-1.htm) |  |  |  |  | X |
| 24.1\* | [Power of Attorney (included on the signature page of this registration statement)](#poa_001) |  |  |  |  | X |
| 99.1 | [Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan\*\*\*](https://www.sec.gov/Archives/edgar/data/1873835/000149315224023947/ex10-1.htm) | 8-K | 001-41159 | 10.1 | 06/14/2024 |  |
| 99.2 | [Form of Stock Option Agreement (Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan) \*\*\*](https://www.sec.gov/Archives/edgar/data/1873835/000149315224028592/ex99-2.htm) | S-8 | 333-280929 | 99.2 | 07/22/2024 |  |
| 99.3 | [Form of Restricted Stock Grant Agreement (Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan) \*\*\*](https://www.sec.gov/Archives/edgar/data/1873835/000149315224028592/ex99-3.htm) | S-8 | 333-280929 | 99.3 | 07/22/2024 |  |
| 99.4 | [Form of Restricted Stock Unit Grant Agreement (Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan) \*\*\*](https://www.sec.gov/Archives/edgar/data/1873835/000149315224028592/ex99-4.htm) | S-8 | 333-280929 | 99.4 | 07/22/2024 |  |
| 107\* | [Filing Fee Table](ex107.htm) |  |  |  |  | X |

---

\* Filed herewith. <br> \*\*\* Indicates management contract or compensatory plan or arrangement.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Los Angeles, State of California on March 25, 2026.

---

| | | |
|:---|:---|:---|
|  | **Immix Biopharma, Inc.** | **Immix Biopharma, Inc.** |
| Date: March 25, 2026 | By: | */s/ Ilya Rachman* |
|  | Name: | Ilya Rachman |
|  | Title: | Chief Executive Officer<br> (Principal Executive Officer) |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that the persons whose signature appears below constitute and appoint Ilya Rachman and Gabriel Morris, and each of them, with full power to act without the other, as such person's true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement, and any and all amendments thereto (including post-effective amendments), and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary or desirable to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Ilya Rachman* | Chief Executive Officer, Chief Scientific Officer and Chairman | March 25, 2026 |
| Ilya Rachman | *(Principal Executive Officer)* |  |
| */s/ Gabriel Morris* | Chief Financial Officer, President and Director | March 25, 2026 |
| Gabriel Morris | *(Principal Financial and Accounting Officer)* |  |
| */s/ Jason Hsu* | Director | March 25, 2026 |
| Jason Hsu |  |  |
| */s/ Magda Marquet* | Director | March 25, 2026 |
| Magda Marquet |  |  |
| */s/ Helen C. Adams* | Director | March 25, 2026 |
| Helen C. Adams |  |  |
| */s/ Carey Ng* | Director | March 25, 2026 |
| Carey Ng |  |  |
| */s/ Jane Buchan* | Director | March 25, 2026 |
| Jane Buchan |  |  |
| */s/ Yekaterina Chudnovsky* | Director | March 25, 2026 |
| Yekaterina Chudnovsky |  |  |
| */s/ Nancy Chang* | Director | March 25, 2026 |
| Nancy Chang |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

1271 Avenue of the Americas

New York, New York 10020

blankrome.com

March 25, 2026

Immix Biopharma, Inc.

11400 West Olympic Blvd., Suite 200

Los Angeles, California 90064

---

| | |
|:---|:---|
| **Re:** | **Immix Biopharma, Inc.—Registration Statement on Form S-8** |

---

Ladies and Gentlemen:

We refer to the Registration Statement on Form S-8 (the "***Registration Statement***") filed on the date hereof by Immix Biopharma, Inc., a Delaware corporation (the "***Company***"), with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "***Securities Ac***t"), with respect to the registration of up to an aggregate of 4,024,556 shares (the "***Shares***") of the Company's common stock, par value $0.0001 per share (the "***Common Stock***"), that may be issued pursuant to the Company's Amended and Restated 2021 Omnibus Equity Incentive Plan, as amended (the "***Plan***").

We have examined originals or certified copies of such corporate records of the Company and other certificates and documents of officials of the Company, public officials and others as we have deemed relevant or appropriate for purposes of this opinion letter. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity to authentic original documents of all copies submitted to us as conformed and certified or reproduced copies. We have also assumed that all of the shares eligible for issuance under the Plan following the date hereof will be issued for not less than par value.

Based upon and subject to the foregoing, we are of the opinion that the Shares which are being offered by the Company pursuant to the Plan and the Registration Statement, when sold in the manner and for the consideration contemplated by the Plan and the Registration Statement, will be validly issued, fully paid and non-assessable. The opinions in this opinion letter are qualified in their entirety and subject to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. We
 express no opinion as to the laws of any jurisdiction other than the General Corporation Law of the State of Delaware.

2. This
 opinion is given as of the date hereof and is limited to the matters stated herein, and no opinion is implied or may be inferred
 beyond the matters expressly stated. We assume herein no obligation, and hereby disclaim any obligation, to make any inquiry after
 the date hereof or to advise you of any future changes in the foregoing or of any facts or circumstances that may hereafter come
 to our attention.

We consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act and the rules and regulations promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ BLANK ROME |
| BLANK ROME LLP |

---

Blank Rome LLP \| blankrome.com

## Exhibit 23.1

**Exhibit 23.1**

<u>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM'S CONSENT</u>

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Immix Biopharma, Inc. of our report dated March 25, 2026 relating to the consolidated financial statements appearing in the Annual Report on Form 10-K of Immix Biopharma, Inc. for the year ended December 31, 2025.

*/s/ Crowe LLP*

Crowe LLP

Los Angeles, California

March 25, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Immix Biopharma, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.0001 par value per share | Other | 4024556 | $8.74 | $35174619.44 | 0.0001381 | $4857.61 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $35174619.44  |  | $4857.61  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $4857.61  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) The securities to be registered include options and other rights to acquire shares of common stock, par value, $0.0001 per share (the "Common Stock"), of Immix Biopharma, Inc. (the "Registrant") issuable pursuant to the Registrant's Amended and Restated 2021 Omnibus Equity Incentive Plan, as amended (the "Plan"). Pursuant to Rule 416 of the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers any additional shares of Common Stock which become issuable by reason of any share dividend, share split, recapitalization or any other similar transaction without receipt of consideration which results in an increase in the number of shares of Common Stock outstanding. Calculated pursuant to Rule 457(c) and 457(h) of the Securities Act solely for purposes of calculating the registration fee. The maximum offering price per share is based on the average of the high and low prices of the common stock as reported on the Nasdaq Capital Market on March 23, 2026. The Registrant does not have any fee offsets to claim.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---